Patents by Inventor Alan M. Ezrin
Alan M. Ezrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8207219Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: GrantFiled: January 19, 2010Date of Patent: June 26, 2012Assignee: Cardiome Pharma Corp.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M. R. Orth, Christian Hesketh
-
Patent number: 8188140Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: GrantFiled: October 7, 2010Date of Patent: May 29, 2012Inventors: Gregory N. Beatch, Alan M. Ezrin
-
Publication number: 20120095073Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: May 18, 2011Publication date: April 19, 2012Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M.R. Orth
-
Publication number: 20110118329Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: ApplicationFiled: October 7, 2010Publication date: May 19, 2011Applicant: CARDIOME PHARMA CORP.Inventors: Gregory N. Beatch, Alan M. Ezrin
-
Publication number: 20100273724Abstract: This invention is directed to PEGlyated derivatives, drug conjugates and isotopic derivatives of certain ion channel modulating compounds.Type: ApplicationFiled: July 7, 2010Publication date: October 28, 2010Applicant: CARDIOME PHARMA CORP.Inventors: Elizabeth L. S. Cheu, Lewis Siu Leung Choi, Doug Ta Hung Chou, Allen W. Davidoff, Alan M. Ezrin, Grace Jung, Bertrand M.C. Plouvier, Aregahegn S. Yifru
-
Patent number: 7820712Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: GrantFiled: November 29, 2007Date of Patent: October 26, 2010Assignee: Cardiome Pharma Corp.Inventors: Gregory N. Beatch, Alan M. Ezrin
-
Patent number: 7786119Abstract: This invention is directed to drug conjugates of certain ion channel modulating compounds having the following formula: wherein A, X, R1, R2, R3, R4, R5, LB, L and DM are defined herein, including isolated enantiomeric and diastereomeric isomers thereof, and mixtures thereof. Pharmaceutical compositions and methods of use are also disclosed.Type: GrantFiled: March 31, 2005Date of Patent: August 31, 2010Assignee: Cardiome Pharma Corp.Inventors: Elizabeth L. S. Cheu, Lewis Siu Leung Choi, Doug Ta Hung Chou, Allen W. Davidoff, Alan M. Ezrin, Grace Jung, Bertrand M. C. Plouvier, Aregahegn S. Yifru
-
Publication number: 20100120890Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: January 19, 2010Publication date: May 13, 2010Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M. R. Orth, Christian Hesketh
-
Patent number: 7674820Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: GrantFiled: August 9, 2004Date of Patent: March 9, 2010Assignee: Cardiome Pharma Corp.Inventors: David Fedida, Gregory N Beatch, Alan M Ezrin, Peter M R Orth, Christian Hesketh
-
Publication number: 20090270478Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: ApplicationFiled: March 20, 2009Publication date: October 29, 2009Applicant: CARDIOME PHARMA CORP.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter M.R. Orth
-
Publication number: 20090175821Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: ApplicationFiled: October 31, 2007Publication date: July 9, 2009Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 7507545Abstract: Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes.Type: GrantFiled: August 9, 2004Date of Patent: March 24, 2009Assignee: Cardiome Pharma Corp.Inventors: David Fedida, Gregory N. Beatch, Alan M. Ezrin, Peter Orth
-
Publication number: 20090041841Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation are disclosed. Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: ApplicationFiled: August 1, 2008Publication date: February 12, 2009Applicant: CARDIOME PHARMA CORP.Inventors: Gregory N. Beatch, Alan M. Ezrin
-
Publication number: 20080188547Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: ApplicationFiled: November 29, 2007Publication date: August 7, 2008Applicant: CARDIOME PHARMA CORP.Inventors: Gregory N. Beatch, Alan M. Ezrin
-
Patent number: 7345086Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.Type: GrantFiled: May 3, 2004Date of Patent: March 18, 2008Assignee: Cardiome Pharma Corp.Inventors: Gregory N. Beatch, Alan M. Ezrin
-
Patent number: 7256253Abstract: A secretin or secretin derivative protected against peptidase activity. The secretin or derivative comprises a peptidic sequence and a reactive group selected from the group consisting of succinimidyl and maleimido groups capable of reacting with an amino group, hydroxyl group or thiol group on a blood component to form a stable covalent bond. The reactive group is attached at a position along the peptidic sequence that provides, when conjugated to a blood component, a higher stability against peptidase degradation than the unconjugated secretin or derivative, and therefore an increased maintenance of the therapeutic activity compared to the unconjugated secretin or derivative. Such a compound is thus effective to provide a source of secretin having a high stability against peptidases. A method for synthesizing such a compound is also described.Type: GrantFiled: February 25, 2005Date of Patent: August 14, 2007Assignee: ConjuChem Biotechnologies Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 6887470Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.Type: GrantFiled: September 7, 2000Date of Patent: May 3, 2005Assignee: Conjuchem, Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 6887849Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: November 4, 2002Date of Patent: May 3, 2005Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
-
Patent number: 6849714Abstract: A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.Type: GrantFiled: May 17, 2000Date of Patent: February 1, 2005Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Alan M. Ezrin, Peter G. Milner, Darren L. Holmes, Karen Thibaudeau
-
Patent number: 6821949Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.Type: GrantFiled: November 4, 2002Date of Patent: November 23, 2004Assignee: ConjuChem, Inc.Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre